アブストラクト
| Title | 高リン血症 |
|---|---|
| Subtitle | 特集 水・電解質を科学する 【水・電解質異常の病態と治療】 |
| Authors | 式田康人**, 溝渕正英** |
| Authors (kana) | |
| Organization | **昭和大学医学部内科学講座 腎臓内科学部門 |
| Journal | 腎と透析 |
| Volume | 90 |
| Number | 5 |
| Page | 908-912 |
| Year/Month | 2021 / 5 |
| Article | 報告 |
| Publisher | 東京医学社 |
| Abstract | 「はじめに」生体内のミネラル代謝において腎臓はきわめて重要な役割を果たしているため, 腎機能が障害される慢性腎臓病 (chronic kidney disease : CKD) においては, さまざまな骨ミネラル代謝異常が生じる. 長期的には血管を含む全身の石灰化を介して生命予後にも影響を及ぼすことから, 2006年にCKD-mineral and bone disorder (CKD-MBD) という疾患概念が提唱された. CKD患者の高リン血症は生命予後や心血管疾患 (cardiovascular disease : CVD) の重大なリスク因子となっており, CKD-MBDにおいても特に重要な病態である. 本稿では, 体内でのリン代謝とともに, 高リン血症が深く関与する病態と対策について概説する. 「I リンの代謝機構」「1. 腎機能正常時」リンは, 生体内のミネラルではカルシウムに次いで多く, 体内に約600g存在する. |
| Practice | 臨床医学：内科系 |
| Keywords | 生命予後, リン制限, リン吸着薬 |
- 全文ダウンロード： 従量制、基本料金制の方共に1,243円(税込) です。
参考文献
- 1) Saurette M, Alexander RT: Intestinal phosphate absorption: The paracellular pathway predominates? Exp Biol Med (Maywood) 244:646-654, 2019
- 2) Palmer SC, Hayen A, Macaskill P, et al: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 305:1119-1127, 2011
- 3) Jono S, McKee MD, Murry CE, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-E17, 2000
- 4) Chertow GM, Burke SK, Raggi P, et al: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
- 5) Block GA, Raggi P, Bellasi A, et al: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71:438-441, 2007
残りの15件を表示する
- 6) Fukagawa M, Komaba H, Onishi Y, et al: Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J Nephrol 33:427-437, 2011
- 7) Li J, Molnar MZ, Zaritsky JJ, et al: Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant 28:1516-1525, 2013
- 8) Weber TJ, Liu S, Indridason OS, et al: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234, 2003
- 9) Gutierrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592, 2008
- 10) Faul C, Amaral AP, Oskouei B, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393-4408, 2011
- 11) 日本透析医学会:慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン.透析会誌 45:301-356, 2012
- 12) Taniguchi M, Fukagawa M, Fujii N, et al: Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial 17:221-228, 2013
- 13) Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl(2011)7:1-59, 2017
- 14) Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al: Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 5:519-530, 2010
- 15) 日本腎臓学会(編):慢性腎臓病に対する食事療法基準2014年版,東京医学社,東京, 2014
- 16) Shinaberger CS, Greenland S, Kopple JD, et al: Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88:1511-1518, 2008
- 17) Moe SM, Zidehsarai MP, Chambers MA, et al: Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6:257-264, 2011
- 18) Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, et al: Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 84:998-1008, 2013
- 19) Isaka Y, Hamano T, Teramukai S, et al: Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol 32:723-735, 2021
- 20) Block GA, Rosenbaum DP, Yan A, et al: Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol 30:641-652, 2019
